This content is from: Premium High-Flying EcoR1 Launching a Blank-Check Company The biopharma specialist headed by one-time II Rising Star Oleg Nodelman continues to beat the major indices. By Stephen Taub June 16, 2020
This content is from: Premium One of the Best-Performing Hedge Funds in Recent Years Just Got Richer Why Avoro Capital Advisors cheered Gilead’s deal to acquire Immunomedics. By Stephen Taub September 16, 2020
This content is from: Premium Two More Hedgies Are Launching SPACs Health care specialist Cormorant and two former Och-Ziff MDs are the latest bandwagon jumpers. By Stephen Taub October 06, 2020
This content is from: Premium Viking Leads Tiger-Related Funds in Latest Biopharma IPO Viking and Matrix Capital Management are the largest outside investors in Adaptive Biotechnologies. By Stephen Taub June 02, 2019
This content is from: Premium Hedge Funds Surface in Wave of Biopharma SPAC Deals RTW and Perceptive Advisors are among investors seen in recent SPAC deals in biopharma. By Stephen Taub October 19, 2020
This content is from: Research These C-Suites Impressed Investors in 2020 The members of the All-America Executive Team prevailed during the pandemic — and earned the respect of institutional investors. By Amy Whyte November 10, 2020
